You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

gilteritinib

Showing 1 - 25 of 29
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

GilteRInf 2022 Study (Gilteritinib Related Infections)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Gilteritinib
  • Roma, RM, Italy
    Maria Ilaria Del Principe
Mar 17, 2023

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)

Suspended
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Tampa, Florida
    Moffitt Cancer Center
Nov 11, 2022

Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Gilteritinib
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2023

Renal Impaired, Gilteritinib, Normal Renal Function Trial in Bulgaria, United States (Gilteritinib)

Active, not recruiting
  • Renal Impaired
  • +3 more
  • Gilteritinib
  • Garden Grove, California
  • +3 more
Jul 27, 2022

Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in United States (Lanraplenib,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Los Angeles, California
  • +3 more
Aug 4, 2022

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
  • gilteritinib
  • +3 more
  • Cincinnati, Ohio
  • +18 more
Jan 20, 2023

Acute Myeloid Leukemia Trial in Houston (Decitabine and Cedazuridine, Enasidenib, Gilteritinib)

Recruiting
  • Acute Myeloid Leukemia
  • Decitabine and Cedazuridine
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Decitabine and Cedazuridine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 19, 2022

Acute Myeloid Leukemia Trial in Memphis (Venetoclax, Azacitidine, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jul 21, 2023

Acute Myeloid Leukemia Trial in United States (Gilteritinib, Midostaurin, Daunorubicin)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Gilteritinib
  • +3 more
  • Scottsdale, Arizona
  • +43 more
Nov 17, 2022

Real World Outcomes Using Novel Agents for AML in the UK

Not yet recruiting
  • Acute Myeloid Leukemia
  • London, United Kingdom
    Guy's and St Thomas' NHS Foundation Trust
Mar 28, 2022

Acute Myeloid Leukemia Trial in United States (ERAS-007, ERAS-601, Gilteritinib)

Withdrawn
  • Acute Myeloid Leukemia
  • San Francisco, California
  • +3 more
Jun 13, 2022

Acute Myeloid Leukemia (AML) Trial in United States (Venetoclax, Gilteritinib)

Completed
  • Acute Myeloid Leukemia (AML)
  • Los Angeles, California
  • +10 more
Sep 7, 2021

Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
  • Los Angeles, California
  • +110 more
Jan 26, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 Trial in Worldwide (Gilteritinib, Midostaurin)

Suspended
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome With Excess Blasts-2
  • Adelaide, Australia
  • +193 more
Jan 5, 2023

Healthy Volunteer Trial in Baltimore (gilteritinib, gilteritinib mini tablet)

Completed
  • Healthy Volunteer
  • gilteritinib
  • gilteritinib mini tablet
  • Baltimore, Maryland
    EPCU - Parexel
Jun 22, 2020

Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in

Recruiting
  • Acute Biphenotypic Leukemia
  • +13 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2023

Advanced Solid Tumors, Acute Myeloid Leukemia Trial in United States (Gilteritinib)

Completed
Has Results
  • Advanced Solid Tumors
  • Acute Myeloid Leukemia
  • Gilteritinib
  • Phoenix, Arizona
  • +6 more
Sep 16, 2021

Leukemia, Myeloid, Acute Trial in Worldwide (CC-90009, Venetoclax, Azacitidine)

Recruiting
  • Leukemia, Myeloid, Acute
  • San Francisco, California
  • +25 more
Jan 9, 2023

Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia Trial in Japan, Korea, Republic of, Taiwan (gilteritinib,

Active, not recruiting
  • Acute Myeloid Leukemia
  • FLT3-mutated Acute Myeloid Leukemia
  • gilteritinib
  • +2 more
  • Anjo, Aichi, Japan
  • +54 more
Jan 10, 2023

Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations Trial in Canada, Japan, United States (gilteritinib)

Approved for marketing
  • Acute Myeloid Leukemia (AML)
  • FMS-like Tyrosine Kinase-3 (FLT3) Mutations
  • gilteritinib
  • Los Angeles, California
  • +38 more
Apr 18, 2021

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide (gilteritinib, LoDAC (Low Dose

Active, not recruiting
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
  • gilteritinib
  • +3 more
  • Beijing, China
  • +47 more
Aug 17, 2022

Leukemia, Acute Myeloid (AML) Trial in Worldwide (gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine)

Active, not recruiting
Has Results
  • Leukemia, Acute Myeloid (AML)
  • gilteritinib
  • +4 more
  • Birmingham, Alabama
  • +125 more
Aug 9, 2022

Advanced Solid Tumors, Pharmacokinetics of 14C-labeled Gilteritinib Trial in Cleveland (gilteritinib, 14C-labeled gilteritinib)

Completed
  • Advanced Solid Tumors
  • Pharmacokinetics of 14C-labeled Gilteritinib
  • gilteritinib
  • 14C-labeled gilteritinib
  • Cleveland, Ohio
    Site US10001
Mar 13, 2019